Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
SOUTH SAN FRANCISCO, Calif., May 01, 2017 -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) announced today that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended March 31, 2017, and provide a general business overview on Monday, May 8, 2017 at 4:30 p.m. ET (1:30 p.m. PT).
Conference Call Details
The live conference call on Monday, May 8, 2017, at 4:30 p.m. Eastern Time, can be accessed by phone by calling (844) 452-6828 from the United States and Canada or 1-765-507-2588 internationally and using the passcode 8594347. The webcast can be accessed live on the Investor Relations section of the Company's website at http://investors.portola.com. It will be archived for 30 days following the call.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXaTM (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. For more information, visit www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact: Ana Kapor Portola Pharmaceuticals [email protected] Media Contact: Julie Normart Pure Communications [email protected] 415.946.1087
